ProQR director reports initial share and option holdings
ProQR Therapeutics N.V. director Valerio Domenico filed an initial ownership report showing his equity position in the company.
Rhea-AI Filing Summary
ProQR Therapeutics N.V. director Valerio Domenico filed an initial ownership report showing his equity position in the company. He directly holds 420,729 Ordinary Shares and has additional indirect exposure through a Valerio family foundation, for which he disclaims beneficial ownership except for any pecuniary interest.
He also holds multiple employee share options over Ordinary Shares with exercise prices ranging from $1.98 to $15.78 per share and expiration dates between 2026 and 2035. These options give him rights to buy additional shares over time as they vest, aligning part of his compensation with ProQR’s long-term share performance.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (6)
- F1. Shares held by Valerio family foundation, Stichting Administratiekantoor Endavit, for which the Reporting Person is the managing director. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such shares for purposes of Section 16 of the Exchange Act, or for any other purpose.
- F2. Fully vested.
- F3. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F4. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F5. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F6. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 3 filing by Valerio Domenico at PRQR show?
How are Valerio Domenico’s indirect ProQR (PRQR) holdings structured?
Do the options in Valerio Domenico’s PRQR Form 3 vest over time?
AI-generated analysis. How Rhea-AI works. Not financial advice.
